Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) announces participation in a live investor webinar focused on Duchenne muscular dystrophy (DMD) on December 4, 2024, at 2:00 pm ET. The webinar will feature key opinion leaders discussing three main topics: new treatment approaches for DMD, patient navigation of clinical trials, and Satellos' novel small molecule approach focusing on muscle regeneration.
Featured speakers include Elijah Stacy, a DMD patient advocate and Founder of Destroy Duchenne, Dr. Michael Rudnicki, Scientific Founder of Satellos and Director of Regenerative Medicine at Ottawa Hospital Research Institute, and Dr. Jordan Dubow, Satellos' CMO. The event will include a Q&A session and is free to attend.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) annuncia la partecipazione a un webinar dal vivo per investitori, incentrato sulla distrofia muscolare di Duchenne (DMD), che si terrà il 4 dicembre 2024, alle 14:00 ET. Il webinar presenterà leader d'opinione chiave che discuteranno tre argomenti principali: nuovi approcci terapeutici per la DMD, la navigazione dei pazienti attraverso le sperimentazioni cliniche e l'innovativo approccio delle piccole molecole di Satellos focalizzato sulla rigenerazione muscolare.
I relatori principali includono Elijah Stacy, un avvocato dei pazienti affetti da DMD e fondatore di Destroy Duchenne, Dr. Michael Rudnicki, fondatore scientifico di Satellos e direttore della Medicina Rigenerativa presso l'Ottawa Hospital Research Institute, e Dr. Jordan Dubow, CMO di Satellos. L'evento prevede una sessione di domande e risposte ed è gratuito per i partecipanti.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) anuncia su participación en un seminario web en vivo para inversionistas centrado en la distrofia muscular de Duchenne (DMD) el 4 de diciembre de 2024 a las 2:00 p.m. ET. El seminario contará con líderes de opinión clave que discutirán tres temas principales: nuevos enfoques de tratamiento para DMD, la navegación de los pacientes a través de ensayos clínicos y el novedoso enfoque de pequeñas moléculas de Satellos enfocado en la regeneración muscular.
Los oradores destacados incluyen a Elijah Stacy, un defensor de pacientes con DMD y fundador de Destroy Duchenne, Dr. Michael Rudnicki, fundador científico de Satellos y director de Medicina Regenerativa en el Ottawa Hospital Research Institute, y Dr. Jordan Dubow, CMO de Satellos. El evento incluirá una sesión de preguntas y respuestas y es gratuito para asistir.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF)는 뒤셴 근육형성증(DMD)에 초점을 맞춘 라이브 투자자 웨비나에 2024년 12월 4일 오후 2시 ET에 참여한다고 발표했습니다. 웨비나는 DMD에 대한 새로운 치료 접근법, 임상 시험에서의 환자 내비게이션, 근육 재생을 중심으로 한 Satellos의 혁신적인 소분자 접근법 등 세 가지 주요 주제를 다룬 주요 의견 리더들의 논의로 진행됩니다.
주요 연사로는 DMD 환자 옹호자이자 Destroy Duchenne의 창립자인 Elijah Stacy, Satellos의 과학적 창립자이자 오타와 병원 연구소의 재생 의학 책임자인 Dr. Michael Rudnicki, 그리고 Satellos의 CMO인 Dr. Jordan Dubow가 포함됩니다. 이 행사에는 질의응답 세션이 포함되어 있으며 참가비는 무료입니다.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) annonce sa participation à un webinaire en direct pour les investisseurs axé sur la dystrophie musculaire de Duchenne (DMD) le 4 décembre 2024 à 14h00 ET. Le webinaire mettra en vedette des leaders d'opinion qui discuteront de trois sujets principaux : de nouvelles approches de traitement pour la DMD, la navigation des patients à travers les essais cliniques et l'approche novatrice de petites molécules de Satellos axée sur la régénération musculaire.
Les intervenants comprendront Elijah Stacy, défenseur des patients DMD et fondateur de Destroy Duchenne, Dr. Michael Rudnicki, fondateur scientifique de Satellos et directeur de la médecine régénérative à l'Institut de recherche de l'hôpital d'Ottawa, ainsi que Dr. Jordan Dubow, CMO de Satellos. L'événement comprendra une session de questions et réponses et est gratuit pour y assister.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) kündigt die Teilnahme an einem Live-Webinar für Investoren an, das sich am 4. Dezember 2024 um 14:00 Uhr ET auf die Duchenne-Muskeldystrophie (DMD) konzentriert. Das Webinar wird führende Meinungsbildner präsentieren, die drei Hauptthemen erörtern: neue Behandlungsansätze für DMD, Patientenführung durch klinische Studien und Satellos' neuartigen Ansatz mit kleinen Molekülen zur Muskelregeneration.
Zu den Hauptrednern gehören Elijah Stacy, ein Patientenanwalt für DMD und Gründer von Destroy Duchenne, Dr. Michael Rudnicki, wissenschaftlicher Gründer von Satellos und Direktor für Regenerative Medizin am Ottawa Hospital Research Institute, sowie Dr. Jordan Dubow, CMO von Satellos. Die Veranstaltung wird eine Fragen-und-Antworten-Runde umfassen und die Teilnahme ist kostenlos.
- None.
- None.
Registration for the event is available at the following link: https://propthink.clickmeeting.com/duchenne-kol-investor-call/register
The live event, hosted by PropThink Digital Conferences (the "Host"), will take place on Wednesday, December 4, 2024, at 2:00 pm ET, and focus on three crucial topics:
1. The persistent need for new approaches to the treatment of DMD that can potentially provide added functional benefit for patients;
2. How patients navigate the current clinical trial and drug development landscape in DMD; and
3. Why the Company's novel, small molecule approach, focused on muscle regeneration, unlocks a new understanding of DMD disease progression and provides a novel therapeutic approach for addressing it.
Key Opinion Leaders Presenting
Elijah Stacy, a DMD patient, author, patient advocate, industry consultant, and Founder of non-profit Destroy Duchenne will join Dr. Michael Rudnicki, a world thought-leader on muscle stem cell function & regeneration, the Scientific Founder of Satellos, and the Director of Regenerative Medicine at the Ottawa Hospital Research Institute and Satellos’ CMO Dr. Jordan Dubow, a renowned neurologist with an extensive regulatory and clinical-development track-record including at AbbVie/Abbott (NASDAQ: ABBV), Cynapsus Therapeutics (acquired by Sunovion for
How to Join
Join the complimentary KOL call by registering here.
Participate & Ask the KOLs Questions, Live.
Participants will have the opportunity to ask Elijah and Drs. Rudnicki and Dubow questions following the Host's prepared remarks, when the live webinar is opened to Q&A from participants.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company’s lead drug candidate SAT-3247 is currently in clinical development as a potential disease-modifying treatment DMD. Additionally, Satellos is leveraging its breakthrough research in muscle stem cell polarity and proprietary discovery platform MyoReGenX™, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.
Notice on Forward-Looking Statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to unlock a new understanding of DMD disease progression and provides a novel therapeutic approach for addressing it; the advancement SAT-3247 in clinical trials; the potential of our approach in other degenerative muscle diseases or in muscle injury or trauma; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; the utility of regenerating muscle by modulating polarity; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” , “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the “Risk Factors” section of Satellos’ Annual Information Form dated March 26, 2024 (which is located on Satellos’ profile at www.sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202453289/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091
Source: Satellos Bioscience Inc.
FAQ
When is Satellos Bioscience (MSCLF) hosting their Duchenne KOL investor webinar?
Who are the key speakers at Satellos' (MSCLF) December 2024 DMD webinar?
What topics will be covered in Satellos' (MSCLF) December 2024 DMD webinar?
Is Satellos' (MSCLF) December 2024 DMD investor webinar free to attend?
